<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="[2], [3], Correspondence: Silvia Benemei, Headache Center, Careggi University Hospital," exact="Department of Health" post="Sciences, University of Florence, Viale Pieraccini 18, 50139 Florence,"/>
 <result pre="The recent release of marketing authorization from both the US" exact="Food and Drug Administration" post="(erenumab, galcanezumab) and the European Medicines Agency (erenumab) for"/>
 <result pre="J Headache Pain 2018 19 1 121 30594122 89 collab:" exact="Eli Lilly and Company" post="AAN 2018: Lillyâ€™s galcanezumab significantly reduced monthly migraine headache"/>
 <result pre="studies Headache 2019 59 2 192 204 30462830 91 collab:" exact="Eli Lilly and Company" post="A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant"/>
 <result pre="ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT03559257 Accessed August 25, 2018 92 collab:" exact="Eli Lilly and Company" post="A Study of Galcanezumab (LY2951742) in Participants 6 to"/>
 <result pre="ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT03432286 Accessed August 25, 2018 93 collab:" exact="Eli Lilly and Company" post="A Study of LY2951742 in Participants With Episodic Cluster"/>
 <result pre="ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT02397473 Accessed August 25, 2018 94 collab:" exact="Eli Lilly and Company" post="A Study of LY2951742 in Participants With Chronic Cluster"/>
 <result pre="ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT02438826 Accessed August 25, 2018 95 collab:" exact="Eli Lilly and Company" post="A Study of LY2951742 (Galcanezumab) in Participants With Cluster"/>
</results>
